Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Acquisitions & Divestments (2022 - 2023)

Neuroone Medical Technologies (NMTC) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $1.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $1.0 million, compared with a TTM value of $4.5 million through Sep 2023, changed N/A, and an annual FY2023 reading of $4.5 million, up 800.0% over the prior year.
  • Change in Acquisitions & Divestments was $1.0 million for Q2 2023 at Neuroone Medical Technologies, down from $2.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $2.0 million in Q1 2023 and bottomed at $1.0 million in Q2 2023.